Investment Analysts’ Weekly Ratings Changes for Roivant Sciences (ROIV)

Roivant Sciences (NASDAQ: ROIV) recently received a number of ratings updates from brokerages and research firms:

• 9/16/2026 – Roivant Sciences is now covered by Stifel Nicolaus. They set a “buy” rating and a $51.00 price target on the stock.
• 9/9/2026 – Roivant Sciences had its price target raised by Guggenheim from $42.00 to $46.00. They now have a “buy” rating on the stock.
• 9/9/2026 – Roivant Sciences was given a new $55.00 price target by UBS Group AG.
• 9/9/2026 – Roivant Sciences had its price target raised by TD Cowen from $50.00 to $55.00. They now have a “buy” rating on the stock.
• 9/8/2026 – Roivant Sciences had its price target raised by HC Wainwright from $41.00 to $47.00. They now have a “buy” rating on the stock.
• 9/8/2026 – Roivant Sciences had its price target raised by Jefferies Financial Group Inc. from $42.00 to $52.00. They now have a “buy” rating on the stock.
• 8/28/2026 – Roivant Sciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $41.00 price target on the stock.
• 8/25/2026 – Roivant Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 8/19/2026 – Roivant Sciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/10/2026 – Roivant Sciences had its price target raised by Citigroup Inc. from $42.00 to $46.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Roivant Sciences had its price target raised by HC Wainwright from $34.00 to $41.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Roivant Sciences had its price target raised by Guggenheim from $36.00 to $42.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Roivant Sciences had its “buy” rating reaffirmed by TD Cowen.
• 7/31/2026 – Roivant Sciences had its “neutral” rating reaffirmed by Bank of America Corporation.
• 7/29/2026 – Roivant Sciences was upgraded by Sanford C. Bernstein to “strong-buy”.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00. Following the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $56,376,551.85. This trade represents a 11.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mayukh Sukhatme sold 284,707 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the completion of the sale, the insider owned 18,630,739 shares in the company, valued at approximately $675,364,288.75. This trade represents a 1.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,860,851 shares of company stock worth $100,825,494 in the last 90 days. Company insiders own 8.80% of the company’s stock.

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.